Repligen (RGEN) EBITDA Margin: History & Chart

Repligen Corporation(RGEN)

Medical - Instruments & Supplies · Waltham, MA

$176.72-12.78 (-6.75%)

Delayed quote: Oct 6, 2026, 3:05 PM EDT

About Repligen Corporation

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Waltham, MA

2,000 employees

www.repligen.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Olivier Loeillot

View full financials

RGEN EBITDA Margin Metrics

EBITDA MARGIN

18.74%

EBITDA MARGIN AVG TTM

19.45%

EBITDA MARGIN AVG 3Y

17.12%

EBITDA MARGIN AVG 5Y

21.52%

EBITDA MARGIN AVG 10Y

22.50%

EBITDA MARGIN AVG 15Y

22.55%

EBITDA MARGIN AVG 20Y

18.52%

CURRENT VS TTM AVG

-3.63%

CURRENT VS 3Y AVG

+9.43%

CURRENT VS 5Y AVG

-12.92%

CURRENT VS 10Y AVG

-16.71%

CURRENT VS 15Y AVG

-16.88%

CURRENT VS 20Y AVG

+1.21%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Repligen Corporation (RGEN)	$9.97B	18.74%	19.45%	17.12%	21.52%
The Ensign Group, Inc. (ENSG)vs ›	$10.03B	10.47%	10.43%	10.38%	10.85%
Bio-Rad Laboratories, Inc. (BIO)vs ›	$9.94B	18.42%	17.41%	19.12%	20.05%
Align Technology, Inc. (ALGN)vs ›	$10.21B	19.75%	19.29%	19.87%	21.06%
Molina Healthcare, Inc. (MOH)vs ›	$10.21B	2.15%	3.41%	4.20%	4.49%
ImmunityBio, Inc. (IBRX)vs ›	$10.30B	-212.29%	-1213.73%	-49114.16%	-44116.26%
Globus Medical, Inc. (GMED)vs ›	$10.33B	20.41%	18.54%	20.94%	21.85%
10x Genomics, Inc. (TXG)vs ›	$10.19B	-10.43%	-17.56%	-24.27%	-20.72%
Henry Schein, Inc. (HSIC)vs ›	$9.64B	8.11%	8.11%	8.28%	8.19%
Krystal Biotech, Inc. (KRYS)vs ›	$9.61B	43.13%	34.03%	-45.57%	-45.57%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Repligen Corporation (RGEN)

$9.97B

18.74%

19.45%

17.12%

21.52%

The Ensign Group, Inc. (ENSG)vs ›

$10.03B

10.47%

10.43%

10.38%

10.85%

Bio-Rad Laboratories, Inc. (BIO)vs ›

$9.94B

18.42%

17.41%

19.12%

20.05%

Align Technology, Inc. (ALGN)vs ›

$10.21B

19.75%

19.29%

19.87%

21.06%

Molina Healthcare, Inc. (MOH)vs ›

$10.21B

2.15%

3.41%

4.20%

4.49%

ImmunityBio, Inc. (IBRX)vs ›

$10.30B

-212.29%

-1213.73%

-49114.16%

-44116.26%

Globus Medical, Inc. (GMED)vs ›

$10.33B

20.41%

18.54%

20.94%

21.85%

10x Genomics, Inc. (TXG)vs ›

$10.19B

-10.43%

-17.56%

-24.27%

-20.72%

Henry Schein, Inc. (HSIC)vs ›

$9.64B

8.11%

8.28%

8.19%

Krystal Biotech, Inc. (KRYS)vs ›

$9.61B

43.13%

34.03%

-45.57%

EBITDA Margin FAQ

What is the EBITDA margin for Repligen Corporation (RGEN)?

The EBITDA margin for RGEN stock is 18.74%.

Is Repligen Corporation's EBITDA margin high or low?

The EBITDA margin of 18.74% is 13% below its 5-year average of 21.52%, around the middle of its 5-year range (-0.74%–36.25%).

What is the TTM average EBITDA margin for Repligen Corporation (RGEN)?

The TTM average EBITDA margin for RGEN stock is 19.45%.

What is the 3Y average EBITDA margin for Repligen Corporation (RGEN)?

The 3Y average EBITDA margin for RGEN stock is 17.12%.

What is the 5Y average EBITDA margin for Repligen Corporation (RGEN)?

The 5Y average EBITDA margin for RGEN stock is 21.52%.

What is the 10Y average EBITDA margin for Repligen Corporation (RGEN)?

The 10Y average EBITDA margin for RGEN stock is 22.50%.

What is the 15Y average EBITDA margin for Repligen Corporation (RGEN)?

The 15Y average EBITDA margin for RGEN stock is 22.55%.

What is the 20Y average EBITDA margin for Repligen Corporation (RGEN)?

The 20Y average EBITDA margin for RGEN stock is 18.52%.

DATE	EBITDA MARGIN
2026-06-30	12.84%
2026-03-31	21.89%
2025-12-31	19.46%
2025-09-30	21.84%
2025-06-30	21.20%
2025-03-31	17.60%
2024-12-31	-0.74%
2024-09-30	6.19%
2024-06-30	18.09%
2024-03-31	16.36%
2023-12-31	10.44%
2023-09-30	17.36%
2023-06-30	22.23%
2023-03-31	17.67%
2022-12-31	33.85%
2022-09-30	32.55%
2022-06-30	36.25%
2022-03-31	34.80%
2021-12-31	25.98%
2021-09-30	30.98%
2021-06-30	35.12%
2021-03-31	31.42%
2020-12-31	27.46%
2020-09-30	30.48%
2020-06-30	29.75%
2020-03-31	24.05%
2019-12-31	17.19%
2019-09-30	19.73%
2019-06-30	22.48%
2019-03-31	25.37%
2018-12-31	22.83%
2018-09-30	23.76%
2018-06-30	17.19%
2018-03-31	22.16%
2017-12-31	17.77%
2017-09-30	7.35%
2017-06-30	22.09%
2017-03-31	23.73%
2016-12-31	17.17%
2016-09-30	20.77%
2016-06-30	24.59%
2016-03-31	18.38%
2015-12-31	12.00%
2015-09-30	24.43%
2015-06-30	26.81%
2015-03-31	24.93%
2014-12-31	6.81%
2014-09-30	21.77%
2014-06-30	26.16%
2014-03-31	37.98%
2013-12-31	39.18%
2013-09-30	46.77%
2013-06-30	38.80%
2013-03-31	26.52%
2012-12-31	38.94%
2012-09-30	20.42%
2012-06-30	14.11%
2012-03-31	15.53%
2011-09-30	11.10%
2011-06-30	3.72%
2011-03-31	-28.55%
2010-12-31	10.78%
2010-09-30	12.78%
2010-06-30	18.42%
2010-03-31	-28.25%
2009-12-31	-18.34%
2009-09-30	-16.16%
2009-06-30	-21.83%
2009-03-31	-63.58%
2008-12-31	-4.29%
2008-09-30	-1.24%
2008-06-30	60.02%
2008-03-31	-110.18%
2007-12-31	-16.97%
2007-09-30	-657.99%
2007-06-30	2.91%
2007-03-31	-5.33%
2006-12-31	-3.21%
2006-09-30	-33.81%
2006-06-30	0.11%
2006-03-31	-30.60%
2005-12-31	-10.80%
2005-09-30	-20.94%
2005-06-30	22.89%
2005-03-31	-15.17%
2004-12-31	-40.23%
2004-09-30	-123.15%
2004-06-30	-15.85%
2004-03-31	-151.40%
2003-12-31	-149.58%
2003-09-30	-140.15%
2003-06-30	-91.70%
2003-03-31	-76.58%
2002-12-31	-28.47%
2002-09-30	-61.50%

DATE

EBITDA MARGIN

2026-06-30

12.84%

2026-03-31

21.89%

2025-12-31

19.46%

2025-09-30

21.84%

2025-06-30

21.20%

2025-03-31

17.60%

2024-12-31

-0.74%

2024-09-30

6.19%

2024-06-30

18.09%

2024-03-31

16.36%

2023-12-31

10.44%

2023-09-30

17.36%

2023-06-30

22.23%

2023-03-31

17.67%

2022-12-31

33.85%

2022-09-30

32.55%

2022-06-30

36.25%

2022-03-31

34.80%

2021-12-31

25.98%

2021-09-30

30.98%

2021-06-30

35.12%

2021-03-31

31.42%

2020-12-31

27.46%

2020-09-30

30.48%

2020-06-30

29.75%

2020-03-31

24.05%

2019-12-31

17.19%

2019-09-30

19.73%

2019-06-30

22.48%

2019-03-31

25.37%

2018-12-31

22.83%

2018-09-30

23.76%

2018-06-30

17.19%

2018-03-31

22.16%

2017-12-31

17.77%

2017-09-30

7.35%

2017-06-30

22.09%

2017-03-31

23.73%

2016-12-31

17.17%

2016-09-30

20.77%

2016-06-30

24.59%

2016-03-31

18.38%

2015-12-31

12.00%

2015-09-30

24.43%

2015-06-30

26.81%

2015-03-31

24.93%

2014-12-31

6.81%

2014-09-30

21.77%

2014-06-30

26.16%

2014-03-31

37.98%

2013-12-31

39.18%

2013-09-30

46.77%

2013-06-30

38.80%

2013-03-31

26.52%

2012-12-31

38.94%

2012-09-30

20.42%

2012-06-30

14.11%

2012-03-31

15.53%

2011-09-30

11.10%

2011-06-30

3.72%

2011-03-31

-28.55%

2010-12-31

10.78%

2010-09-30

12.78%

2010-06-30

18.42%

2010-03-31

-28.25%

2009-12-31

-18.34%

2009-09-30

-16.16%

2009-06-30

-21.83%

2009-03-31

-63.58%

2008-12-31

-4.29%

2008-09-30

-1.24%

2008-06-30

60.02%

2008-03-31

-110.18%

2007-12-31

-16.97%

2007-09-30

-657.99%

2007-06-30

2.91%

2007-03-31

-5.33%

2006-12-31

-3.21%

2006-09-30

-33.81%

2006-06-30

0.11%

2006-03-31

-30.60%

2005-12-31

-10.80%

2005-09-30

-20.94%

2005-06-30

22.89%

2005-03-31

-15.17%

2004-12-31

-40.23%

2004-09-30

-123.15%

2004-06-30

-15.85%

2004-03-31

-151.40%

2003-12-31

-149.58%

2003-09-30

-140.15%

2003-06-30

-91.70%

2003-03-31

-76.58%

2002-12-31

-28.47%

2002-09-30

-61.50%

EBITDA Margin: 18.74%

RGEN EBITDA Margin

RGEN Average EBITDA Margin Chart

RGEN Current vs Average EBITDA Margin Chart

RGEN EBITDA Margin Metrics

RGEN Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

RGEN EBITDA Margin History

Related Metrics